GT Biopharma

Washington, United States Founded: 1965 • Age: 61 yrs Listed
Immunotherapies for cancer treatment are developed using proprietary platforms.

About GT Biopharma

GT Biopharma is a publicly listed company based in Washington (United States) founded in 1965 by Anthony Cataldo. Immunotherapies for cancer treatment are developed using proprietary platforms. The company has 1 employees. GT Biopharma offers products and services including TriKE Therapies. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory. Its legal entity in India is G T Biopharma Private Limited (U24234DL2007PTC165068). Similar companies include Moderna, Roivant Sciences and BeiGene; 3 of its 3 listed similar companies have raised funding.

Company details

GT Biopharma was founded in 1965 and operates in the biotechnology sector, where immunotherapies are developed for cancer treatment. Proprietary platform technology is utilized to create biopharmaceutical drugs targeting conditions such as acute lymphocytic leukemia, non-Hodgkins lymphoma, acute myeloid leukemia, and various solid tumors. Operations focus on immuno-oncology advancements without specified geographic limitations.

  • Headquarters Washington, United States
  • Employees 1
  • Founders Anthony Cataldo
  • Stage Public
  • Sectors
    Healthcare
  • Website gtbiopharma.com
  • Social LinkedIn X
  • Legal Name Gt Biopharma, Inc.
Key Metrics
  • Net Profit
    -$28.35 M (USD)
    -115.42
    as on Dec 31, 2025
  • EBITDA
    -$12.42 M (USD)
    13.52
    as on Dec 31, 2025
  • Latest Funding Round
    $5.95M (USD), Post-IPO

    May 2025

  • Employee Count
    1

Products & Services of GT Biopharma

GT Biopharma offers a comprehensive portfolio of products and services, including TriKE Therapies.

TriKE Therapies
Immunotherapy

Biopharmaceutical agents that engage NK cells to target and kill cancer cells.

Funding Insights of GT Biopharma

  • Total Rounds 9
  • Last Round Post-IPO โ€” $5.95M
  • First Round $1.43M

    (Jul 2014)

All 9 funding rounds of GT Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2025$5.95MPost-IPOโ€“โ€“
โ€“
Feb 2025$1.28MPost-IPOโ€“โ€“
โ€“
Jul 2020$2.42MPost-IPOโ€“โ€“
โ€“
Feb 2019$1.05MPost-IPOโ€“โ€“
โ€“
Aug 2018$5.14MPost-IPOโ€“โ€“
โ€“
Feb 2018$7.06MPost-IPOโ€“โ€“
โ€“
Sep 2017$4.54MPost-IPOโ€“โ€“
โ€“
Mar 2015$2.05MPost-IPOโ€“โ€“
โ€“
Jul 2014$1.43MPost-IPOโ€“โ€“
โ€“

Board of directors of G T Biopharma Private Limited (GT Biopharma)

G T Biopharma Private Limited is the primary company behind GT Biopharma. The board of G T Biopharma Private Limited currently have 2 directors; the longest-serving is Mukesh Bhasin, appointed in 2007. 8 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Mukesh Bhasin
DIN 01061327
Director21 Jun 200719 yrs 4 moG T Biopharma Private Limited
Sanjay Kumar Bhartia
DIN 00275439
Director21 Jun 200719 yrs 4 moG T Biopharma Private Limited

People of GT Biopharma

12 people are tracked at GT Biopharma (5 in leadership, 4 in board & advisors, 3 in team); the tracked headcount is 1.

NameRoleGroup
Anthony Cataldo
FounderLeadership
Manu Ohri
CFOLeadership
Michael Breen
Executive Chairman & Interim CEOLeadership
Gavin Choy
Chief Clinical Development OfficerLeadership
Alan L. Urban
Chief Financial OfficerLeadership
Lisa A. Haile
Scientific AdvisorBoard & advisors
Arjun V Balar
Scientific AdvisorBoard & advisors
Philip Werthman
Scientific AdvisorBoard & advisors
Samir Taneja
Scientific AdvisorBoard & advisors
Jeffrey S. Miller
Consulting CSOTeam
Stacy Herb
SVP, Portfolio ManagementTeam
Julianne Feola
Clinical Operations ConsultantTeam
Premium access

Complete people profiles for GT Biopharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of GT Biopharma

GT Biopharma is a publicly listed company on the NASDAQ with ticker symbol GTBP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date22 Oct 2013
  • Listed onNASDAQ: GTBP
  • Listed entityGT Biopharma, Inc.
  • Exchange sectorHealth technology
  • ISINUS36254L4077
  • Share price$6.50 (-4.41% on the day) · 2026-10-13
  • Market capitalisation$13.4M
  • EPS (diluted, trailing year)$-90.07
  • Volume (last session)29,555

Financials of GT Biopharma

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025-$28.4M-$12.4M
2024-$13.2M-$14.4M
2023-$7.6M-$13.6M
2022-$20.9M-$21.3M
2021-$58.0M-$57.8M

Balance sheet, profit and loss, cash flow and ratios of G T Biopharma Private Limited are on its company page.

Premium access

Detailed financial statements for GT Biopharma

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of GT Biopharma

4 dated milestones of GT Biopharma across 60 years, from founding to its latest funding, stage changes and deals.

  1. Founded GT Biopharma is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $1.4M.
  4. Funding Latest funding round, Post-IPO, of $6.0M.

Similar companies to GT Biopharma

GT Biopharma has 3 listed similar companies in our database, 3 of them funded. They include Moderna, Roivant Sciences and BeiGene.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
roivant.com2014New York, United States$1.3B662
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
Premium access

Detailed similar companies of GT Biopharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of GT Biopharma

The website of GT Biopharma (gtbiopharma.com) receives about 3.7K visits a month.

  • Monthly visits
    3.7K

    ▼ 26.7% vs previous month

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as GT Biopharma (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track โ€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • โœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • โœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • โœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Gt Biopharma

Premium access

Complete news archive for GT Biopharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about GT Biopharma

GT Biopharma was founded in 1965 and raised its 1st funding round 49 years after it was founded.

GT Biopharma is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.

GT Biopharma has 1 employees.

GT Biopharma was founded in 1965 and operates in the biotechnology sector, where immunotherapies are developed for cancer treatment. Proprietary platform technology is utilized to create biopharmaceutical drugs targeting conditions such as acute lymphocytic leukemia, non-Hodgkins lymphoma, acute myeloid leukemia, and various solid tumors. Operations focus on immuno-oncology advancements without specified geographic limitations.

GT Biopharma's top competitors include Moderna, Roivant Sciences and BeiGene.

GT Biopharma offers TriKE Therapies.

Yes, GT Biopharma is publicly traded on NASDAQ under the ticker symbol GTBP.

GT Biopharma operates through G T Biopharma Private Limited.

The legal entities of GT Biopharma currently have 2 directors, including Mukesh Bhasin, Sanjay Kumar Bhartia.

Explore millions of companies โ€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals โ€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available